Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: Influence of pH and NaCl concentration

Pharmaceutical Research

Volumn 21, Issue 5, 2004, Pages 844-850

  Nugroho, Akhmad Khans ^a,b   Gai, Ling Li ^a   Danhof, Meindert ^a   Bouwstra, Joke A ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

Dopamine receptor agonist; Electro osmosis; Electro repulsion; Lipophilicity; Parkinson's disease

Indexed keywords

BUFFER; DOPAMINE RECEPTOR STIMULATING AGENT; MANNITOL; PHOSPHATE; ROTIGOTINE; SODIUM CHLORIDE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DENSITY; DRUG DIFFUSION; DRUG SOLUBILITY; DRUG TRANSPORT; ELECTRIC CURRENT; ELECTROOSMOSIS; HUMAN; HUMAN TISSUE; IONTOPHORESIS; LIPOPHILICITY; PH; PRIORITY JOURNAL; SKIN PERMEABILITY; STEADY STATE; STRATUM CORNEUM;

ADMINISTRATION, CUTANEOUS; ALGORITHMS; ANTIPARKINSON AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE AGONISTS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; IONTOPHORESIS; KINETICS; OSMOSIS; SKIN ABSORPTION; SODIUM CHLORIDE; SOLUBILITY; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 1842592914     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000026438.57787.10     Document Type: Article

References (32)

1. A. Lledo. Dopamine agonists: the treatment for Parkinson's disease in the XXI century? Parkinsonism Relat. Disord. 7:51-58 (2000).
2. J. Van der Weide, J. B. de Vries, P. G. Tepper, D. N. Krause, M. L. Dubocovich, and A. S. Horn. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models. Eur. J. Pharmacol. 147:249-258 (1988).
3. V. P. Calabrese, K. A. Lloyd, P. Brancazio, E. Cefali, P. Martin, J. J. Wall, and D. Sica. N-0923. a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov. Disord. 13:768-774 (1998).
4. T. K. Gerding, B. F. Drenth, H. J. Roosenstein, R. A. de Zeeuw, P. G. Tepper, and A. S. Horn. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. I. Disposition and metabolic profiling. Xenobiotica 20:515-524 (1990).
5. T. K. Gerding, B. F. Drenth, R. A. de Zeeuw, P. G. Tepper, and A. S. Horn. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2- thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. II. Isolation and identification of metabolites. Xenobiotica 20:525-536 (1990).
6. P. J. Swart and R. A. de Zeeuw. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 47:613-615 (1992).
7. P. J. Swart, W. E. Oelen, A. P. Bruins, P. G. Tepper, and R. A. de Zeeuw. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J. Anal. Toxicol. 18:71-77 (1994).
8. D. R. Friend. Transdermal delivery of contraceptives. Crit. Rev. Ther. Drug Carrier Syst. 7:149-186 (1990).
9. J. T. Hutton, L. V. Metman, T. N. Chase, J. L. Juncos, W. C. Koller, R. Pahwa, P. A. LeWitt, A. Samii, J. K. Tsui, D. B. Calne, C. H. Waters, V. P. Calabrese, J. P. Bennett, R. Barrett, and J. L. Morris. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. 16:459-463 (2001).
10. L. V. Metman, M. Gillespie, C. Farmer, F. Bibbiani, S. Konitsiotis, M. Morris, H. Shill, W. Bara-Jimenez, M. M. Mouradian, and T. N. Chase. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin. Neuropharmacol. 24:163-169 (2001).
11. P. J. Swart, W. L. Weide, and R. A. de Zeeuw. In vitro penetration of the dopamine D2 agonist N-0923 with and without Azone. Int. J. Pharm. 87:67-72 (1992).
12. B. H. Sage. Iontophoresis. In E. W. Smith and H. I. Maibach (eds.). Percutaneous Penetration Enhancer, CRC Press Inc., Boca Raton, 1995, pp. 351-368.
13. A. Luzardo-Alvarez, M. B. Delgado-Charro, and J. Blanco-Mendez. Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation. Pharm. Res. 18:1714-1720 (2001).
14. R. Van der Geest, M. Danhof, and H. E. Bodde. Iontophoretic delivery of apomorphine. I: In vitro optimization and validation. Pharm. Res. 14:1798-1803 (1997).
15. G. L. Li, M. Danhof, and J. A. Bouwstra. Effect of elastic liquid-state vesicle on apomorphine iontophoresis transport through human skin in vitro. Pharm. Res. 18:1627-1630 (2001).
16. G. L. Li, M. Danhof, and J. A. Bouwstra. Iontophoretic delivery of apomorphine in vitro: physicochemic considerations. Pharm. Res. 18:1509-1513 (2001).
17. G. L. Li, R. Van der Geest, L. Chanet, E. van Zanten, M. Danhof, and J. A. Bouwstra. In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement. J. Control. Rel. 84:49-57 (2002).
18. G. L. Li, M. Danhof, P. M. Frederik, and J. A. Bouwstra. Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro. Pharm. Res. 20:653-659 (2003).
19. R. Van der Geest, T. Van Laar, J. M. Gubbens-Stibbe, H. E. Bodde, and M. Danhof. Iontophoretic delivery of apomorphine. II: an in vivo study in patients with Parkinson's disease. Pharm. Res. 14:1804-1810 (1997).
20. G. L. Li. Transdermal Iontophoretic Delivery of R-Apomorphine for the Treatment of Patients with Parkinson's Disease. Ph.D. Thesis, Leiden University, Leiden, The Netherlands, 2003.
21. R. Van der Geest, M. Danhof, and H. E. Bodde. Validation and testing of a new iontophoretic continuous flow through transport cell. J. Control. Rel. 51:85-91 (1998).
22. N. Kanikkannan, J. Singh, and P. Ramarao. In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species. J. Control. Rel. 71:99-105 (2001).
23. S. Y. Oh, S. Y. Jeong, T. G. Park, and J. H. Lee. Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. J. Control. Rel. 51:161-168 (1998).
24. Anonymous. N-0923 Hydrochloride General Information and Properties, internal report, Schwarz Pharma, 2001.
25. L. Wearley and Y. W. Chien. Enhancement of the in vitro skin permeability of azidothymidine (AZT) via iontophoresis and chemical enhancer. Pharm. Res. 7:34-40 (1990).
26. L. Wearley, L. Jue-Chen, and Y. W. Chien. Iontophoresis-facilitated transdermal delivery of verapamil I. In vitro evaluation and mechanistic studies. J. Control. Rel. 8:237-250 (1989).
27. D. Marro, R. H. Guy and, M. B. Delgado-Charro. Characterization of the iontophoretic permselectivity properties of human and pig skin. J. Controlled Release 70:213-217 (2001).
28. J. Hirvonen and R. H. Guy. Iontophoretic delivery across the skin: electro-osmosis and its modulation by drug substances. Pharm. Res. 14:1258-1263 (1997).
29. D. Marro, Y. N. Kalia, M. B. Delgado-Charro, and R. H. Guy. Contributions of electromigration and electro-osmosis to iontophoretic drug delivery. Pharm. Res. 18:1701-1708 (2001).
30. M. J. Pikal. The role of electroosmotic flow in transdermal iontophoresis. Adv. Drug Deliv. Rev. 46:281-305 (2001).
31. A. Jadoul, L. M. Dunbar, D. Ellis, and V. Preat. Modification induced on stratum corneum structure after in vitro iontophore-sis: ATR-FTIR and X-ray scattering studies. J. Control. Rel. 42:165-173 (1996).
32. A. Jadoul, J. A. Bouwstra, and V. Preat. Effects of iontophoresis and electroporation on the stratum corneum. Review of the biophysical studies. Adv. Drug Deliv. Rev. 35:89-105 (1999).